| Does screening for prostate cancer identify clinically important disease? | |
| | |
MedLine Citation:
|
PMID: 10364958 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In this study the combination of digital rectal examination (DRE) and serum prostate-specific antigen (PSA) is shown to be effective for detecting early prostate cancer in a urological out-patient setting. PSA provides the means to detect cancer in men with normal DRE that may otherwise present as so-called incidental cancer at transurethral resection of the prostate (TURP) for apparently benign disease or later in the course of its natural history as locally advanced or metastatic disease. PSA progression in men with incidental cancer has been previously demonstrated to be predicted more reliably by residual cancer on needle biopsy after TURP than by tumour in the resected specimen and, therefore re-staging such patients is worthwhile when further treatment would be considered. Among men selected for radical prostatectomy, non-palpable tumours detected with PSA more predictable in pathological extent than incidental cancer and their particular pathological characteristics suggest they include clinically significant tumours that would progress if untreated to palpable and eventually metastatic disease. In view of this progressive behaviour, cancer detected by PSA should be considered clinically significant particularly in men with a life expectancy of at least 10 years. Therefore screening should be offered for such individuals, to detect and treat tumours at a curable stage and thereby eliminate the high mortality and often protracted morbidity commonly associated with metastatic disease. |
| | |
Authors:
|
M R Feneley |
Related Documents
:
|
10470208 - Critical aspects related to the interpretation of the free-to-total psa-ratio. 15385308 - Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal mri an... 15120658 - Fever detection from free-text clinical records for biosurveillance. 14993898 - Determining variables for repeat prostate biopsy. 9739758 - The papillomavirus e6 proteins. 2116118 - Massive screening for colorectal cancer. a single institution's public commitment. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Annals of the Royal College of Surgeons of England Volume: 81 ISSN: 0035-8843 ISO Abbreviation: Ann R Coll Surg Engl Publication Date: 1999 May |
Date Detail:
|
Created Date: 1999-06-23 Completed Date: 1999-06-23 Revised Date: 2010-09-10 |
Medline Journal Info:
|
Nlm Unique ID: 7506860 Medline TA: Ann R Coll Surg Engl Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 207-14 Citation Subset: IM |
Affiliation:
|
Brady Urological Institute, Johns Hopkins Hospital, Baltimore, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Biopsy, Needle England / epidemiology Humans Incidence Male Mass Screening* Middle Aged Patient Selection Physical Examination Predictive Value of Tests Prospective Studies Prostate / pathology Prostate-Specific Antigen / blood Prostatectomy Prostatic Intraepithelial Neoplasia / diagnosis* Prostatic Neoplasms / diagnosis*, epidemiology, surgery Sensitivity and Specificity Wales / epidemiology |
| Chemical | |
Reg. No./Substance:
|
EC 3.4.21.77/Prostate-Specific Antigen |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Adenocarcinoma within a rectal duplication cyst: case report and literature review.
Next Document: Square pegs in round holes: has psychometric testing a place in choosing a surgical career? A prelim...